Infectious Disease Treatments Market Research Report – Global Forecast Till 2023

Global Infectious Disease Treatments Market Research Report: Information By Type (Viral Diseases, Bacterial Diseases) Treatment (Antibacterial, Antifungal Drugs, Antiviral Drugs) End Users (Hospitals & Clinics, Retail Pharmacies) – Forecast till 2023

Market Scenario

Infectious diseases can be caused by a variety of organisms that are inclusive of bacteria, viruses, fungi, and parasites. Some infectious diseases are contagious and can be passed from person to person. Few of these infectious diseases are transmitted by the bites of insects or animals while few are also acquired by ingestion of contaminated water or food. Some of the common examples of infectious diseases are acquired immunodeficiency syndrome (AIDS), hepatitis B, tuberculosis (TB), and others. Increasing prevalence of the infectious diseases like TB, AIDS, and others across the globe is one of the major drivers for the growth of the market during the forecast period. In 2016, according to the Centers for Disease Control and Prevention, TB affected one-third of the world’s population. Moreover, it was estimated that 10.4 million people around the world were detected with TB disease and the disease led to 1.7 million, people globally. Additionally, according to the World Health Organisation, in 2016, 36.7 million people lived with HIV/AIDS and the disease caused 1.0 million deaths, globally. Besides this, increasing healthcare expenditures, growing awareness of the patients will further boost the market growth. However, low adoption of the treatment and low per capita healthcare expenditure in the developing economies may restrain the market growth during the forecast period.

The global infectious disease treatments market is expected to grow at an approximate CAGR of 7.1% during the forecast period.

Intended Audience

- Pharmaceutical Companies
- Biotechnological Institutes
- Research and Development (R&D) Companies
- Medical Research Laboratories
- Market Research and Consulting Service Providers

Figure 1:- Global infectious disease treatments market share, by region
Sources: WHO, annual reports, press release, white paper, and company presentation

Segmentation

The global infectious disease treatments market is segmented on the basis of type, treatment, and end users.

On the basis of the type, the market is segmented into viral diseases, bacterial diseases, and others. The viral diseases segment is sub-segmented into acquired immunodeficiency syndrome (AIDS), hepatitis B, hepatitis C, and others. The bacterial diseases segment is sub-segmented into tuberculosis (TB), bacterial meningitis, and others.

On the basis of the treatment, the market is segmented into antibacterial drugs, antifungal drugs, antiviral drugs, anti-parasitic drugs, and others. The antibacterial drugs segment is sub-segmented into beta-lactams, quinolones, sulfonamides, tetracyclines, and others. The antifungal drugs segment is sub-segmented into azoles, pyrimidines, echinodians, polyenes, and others.

On the basis of application, the market is segmented into asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and others.

On the basis of the end users, the market is segmented into hospitals & clinics, research organization, retail pharmacies, and others.

Regional Analysis

The Americas dominate the global infectious disease treatments market. A well-developed healthcare sector and huge patient population for infectious diseases followed by increasing healthcare expenditure and changing lifestyle drive the market growth in the Americas. Moreover, the presence of global players like Merck & Co., Inc., Pfizer Inc., and others within the region fuels the market growth during the forecast period.

Europe is the second largest infectious disease treatments market. High healthcare expenditures, government support for research & development, and huge patient population drives the European market. Moreover, the presence of the developed economies within the region like Germany, the U.K, and France fuels the market growth during the forecast period.

Asia Pacific is the fastest growing region in the global market due to the presence of a huge patient population and continuously developing economies like India and China which have a growing healthcare industry. Additionally, favorable government policies like reduced excise and customs duty followed by the exemptions in service tax in India boosts the regional market growth.

On the other hand, the Middle East & Africa holds the least share in the global infectious disease treatments market due to the presence of poor economies in the African region. Moreover, the low per capita income and stringent government policies restrain the market growth within the African region. A majority of the market in the Middle East & Africa is held by the Middle East due to huge healthcare expenditures and presence of developed economies like Kuwait, Saudi Arabia, Dubai,
and Qatar.

Research Methodology

Sources: WHO, annual reports, press release, white paper, and company presentation

Key players for global infectious disease treatments market

Merck & Co., Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc. (U.S.), GlaxoSmithKline plc. (U.K), AstraZeneca (U.K), Novartis AG (Switzerland), Sanofi (France), Mylan N.V. (U.S.), and others are some of the key players for the global infectious disease treatments market.

Contents:

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Treatment Trends & Assessment

Chapter 5. Market Factor Analysis
5.1 Porters Five Forces Analysis
  5.1.1 Bargaining Power of Suppliers
  5.1.2 Bargaining Power of Buyers
  5.1.3 Threat of New Entrants
  5.1.4 Threat of Substitutes
  5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis

Chapter 6. Global Infectious Disease Treatments, by Type
6.1 Introduction
6.2 Viral Diseases Market Estimates & Forecast, 2017 – 2023
  6.2.1 Acquired Immunodeficiency Syndrome (AIDS)
  6.2.2 Hepatitis B
  6.2.3 Hepatitis C
  6.2.4 Others
6.3 Bacterial Diseases Market Estimates & Forecast, 2017 – 2023
  6.3.1 Tuberculosis (TB)
  6.3.2 Bacterial meningitis
  6.3.3 Others
  6.3.4 Others
6.4 Others

Chapter 7. Global Infectious Disease Treatments, by Treatment
7.1 Introduction
7.2 Antibacterial Drugs Market Estimates & Forecast, 2017 – 2023
  7.2.1 Beta-Lactams
  7.2.2 Quinolones
  7.2.3 Sulfonamides
  7.2.4 Tetracyclines
  7.2.5 Others
7.3 Antifungal Drugs Market Estimates & Forecast, 2017 – 2023
  7.3.1 Azoles
  7.3.2 Pyrimidines
  7.3.3 Echinodians
  7.3.4 Polyenes
  7.3.5 Others
7.4 Antiviral Drugs Market Estimates & Forecast, 2017 – 2023
7.5 Anti-parasitic Drugs Market Estimates & Forecast, 2017 – 2023
7.6 Others

Chapter 8. Global Infectious Disease Treatments, by End Users
8.1 Introduction
8.3 Research Organization Market Estimates & Forecast, 2017 – 2023
8.4 Retail Pharmacies Market Estimates & Forecast, 2017 – 2023
8.5 Others

Chapter 9. Global Infectious Disease Treatments, by Region

9.1 Introduction
9.2 America
9.2.1 North America
9.2.1.1 US
9.2.1.2 Canada
9.2.2 South America
9.3 Europe
9.3.1 Western Europe
9.3.1.1 Germany
9.3.1.2 France
9.3.1.3 Italy
9.3.1.4 Spain
9.3.1.5 U.K
9.3.1.6 Rest of Western Europe
9.3.2 Eastern Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 Republic of Korea
9.4.6 Rest of Asia Pacific
9.5 The Middle East & Africa
9.5.1 United Arab Emirates
9.5.2 Saudi Arabia
9.5.3 Oman
9.5.4 Kuwait
9.5.5 Qatar
9.5.6 Rest of the Middle East & Africa

Chapter 10. Company Landscape

10.1 Introduction
10.2 Market Share Analysis
10.3 Key Development & Strategies
10.3.1 Key Developments

Chapter 11 Company Profiles

11.1 Merck & Co., Inc.
11.1.1 Company Overview
11.1.2 Type Overview
11.1.3 Financials
11.1.4 Key Developments
11.1.5 SWOT Analysis
11.2 F. Hoffmann-La Roche Ltd
11.2.1 Company Overview
LIST OF TABLES
Table 1 Infectious Disease Treatments Industry Synopsis, 2017 – 2023
Table 2 Global Infectious Disease Treatments Estimates and Forecast, 2017 – 2023, (USD Million)
Table 3 Global Infectious Disease Treatments by Region, 2017 – 2023, (USD Million)
Table 4 Global Infectious Disease Treatments by Type, 2017 – 2023, (USD Million)
Table 5 Global Infectious Disease Treatments by Treatment, 2017 – 2023, (USD Million)
Table 6 Global Infectious Disease Treatments by End Users, 2017 – 2023, (USD Million)
Table 7 North America Infectious Disease Treatments Market by Type, 2017 – 2023, (USD Million)
Table 8 North America Infectious Disease Treatments Market by Treatment, 2017 – 2023, (USD Million)
Table 9 North America Infectious Disease Treatments Market by End Users, 2017 – 2023, (USD Million)
Table 10 U.S. Infectious Disease Treatments Market by Type, 2017 – 2023, (USD Million)
Table 11 U.S. Infectious Disease Treatments Market by Treatment, 2017 – 2023, (USD Million)
Table 12 U.S. Infectious Disease Treatments Market by End Users, 2017 – 2023, (USD Million)
Table 13 Canada Infectious Disease Treatments Market by Type, 2017 – 2023, (USD Million)
Table 14 Canada Infectious Disease Treatments Market by Treatment, 2017 – 2023, (USD Million)
Table 15 Canada Infectious Disease Treatments Market by End Users, 2017 – 2023, (USD Million)
Table 16 South America Infectious Disease Treatments Market by Type, 2017 – 2023, (USD Million)
Table 17 South America Infectious Disease Treatments Market by Treatment, 2017 – 2023, (USD Million)
Table 18 South America Infectious Disease Treatments Market by End Users, 2017 – 2023, (USD Million)
Table 19 Europe Infectious Disease Treatments Market by Type, 2017 – 2023, (USD Million)
Table 20 Europe Infectious Disease Treatments Market by Treatment, 2017 – 2023, (USD Million)
Table 21 Europe Infectious Disease Treatments Market by End Users, 2017 – 2023, (USD Million)
Table 22 Western Europe Infectious Disease Treatments Market by Type, 2017 – 2023, (USD Million)
Table 23 Western Europe Infectious Disease Treatments Market by Treatment, 2017 – 2023, (USD Million)
Table 24 Western Europe Infectious Disease Treatments Market by End Users, 2017 – 2023, (USD Million)
Table 25 Eastern Europe Infectious Disease Treatments Market by Type, 2017 – 2023, (USD Million)
Table 26 Eastern Europe Infectious Disease Treatments Market by Treatment, 2017 – 2023, (USD Million)
Table 27 Eastern Europe Infectious Disease Treatments Market by End Users, 2017 – 2023, (USD Million)
Table 28 Asia Pacific Infectious Disease Treatments Market by Type, 2017 – 2023, (USD Million)
Table 29 Asia Pacific Infectious Disease Treatments Market by Treatment, 2017 – 2023, (USD Million)
Table 30 Asia Pacific Infectious Disease Treatments Market by End Users, 2017 – 2023, (USD Million)
Table 31 Middle East & Africa Infectious Disease Treatments Market by Type, 2017 – 2023, (USD Million)
Table 32 Middle East & Africa Infectious Disease Treatments Market by Treatment, 2017 – 2023, (USD Million)
Table 33 Middle East & Africa Infectious Disease Treatments Market by End Users, 2017 – 2023, (USD Million)

LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation for Global Infectious Disease Treatments
Figure 3 Market Dynamics for Global Infectious Disease Treatments
Figure 4 Global Infectious Disease Treatments Share, by Type 2016
Figure 5 Global Infectious Disease Treatments Share, by Treatment 2016
Figure 6 Global Infectious Disease Treatments Share, by End Users, 2016
Figure 7 Global Infectious Disease Treatments Share, by Region, 2016
Figure 8 North America Infectious Disease Treatments Market Share, by Country, 2016
Figure 9 Europe Infectious Disease Treatments Market Share, by Country, 2016
Figure 10 Asia Pacific Infectious Disease Treatments Market Share, by Country, 2016
Figure 11 Middle East & Africa Infectious Disease Treatments Market Share, by Country, 2016
Figure 12 Global Infectious Disease Treatments: Company Share Analysis, 2016 (%)
Figure 13 Merck & Co., Inc.: Key Financials